IsoPlexis Reports Preliminary First Quarter 2022 Revenue, Streamlines Operating Structure to Support Sustainable GrowthGlobeNewsWire • 04/11/22
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022GlobeNewsWire • 04/08/22
IsoPlexis' (ISO) CEO Sean Mackay on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022GlobeNewsWire • 03/02/22
IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022GlobeNewsWire • 02/16/22
IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID in Cell PublicationGlobeNewsWire • 02/10/22
IsoPlexis Strengthens International Reach and Leadership with First APAC Office and Jason Ou as President/General Manager, APAC RegionGlobeNewsWire • 02/02/22
IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell LibraryGlobeNewsWire • 01/10/22
IsoPlexis to Present IsoLight® Single-Cell Proteomics Data at ASH 2021 ConferencePRNewsWire • 12/08/21
IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics CompaniesPRNewsWire • 11/30/21
IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine PublicationsPRNewsWire • 11/18/21
IsoPlexis to Present Data at SITC 2021 Connecting Genetic Drivers to Functional ProteomicsPRNewsWire • 11/05/21
U.S. IPO Weekly Recap: Healthcare And Canadian Crosslistings Lead An 8 IPO WeekSeeking Alpha • 10/09/21
IsoPlexis, a company uncovering a ‘new layer' of cell data, aims for $125M in market debutTechCrunch • 10/08/21
IsoPlexis IPO priced in the middle of expected range, as the biotech raised $125 millionMarket Watch • 10/08/21